BRIEF-Nurix Therapeutics Announces Hart-Scott-Rodino Clearance Of Global Collaboration With Roche To Co-Develop And Co-Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

NRIX

0.00

July 21 (Reuters) - Nurix Therapeutics Inc NRIX.O:

  • NURIX THERAPEUTICS ANNOUNCES HART-SCOTT-RODINO CLEARANCE OF GLOBAL COLLABORATION WITH ROCHE TO CO-DEVELOP AND CO-COMMERCIALIZE POTENTIAL BEST-IN-CLASS BTK DEGRADER BEXOBRUTIDEG ACROSS MALIGNANT HEMATOLOGY, IMMUNOLOGY AND NEUROLOGY

  • NURIX THERAPEUTICS - TO RECEIVE $700 MILLION UPFRONT, UP TO $2.30 BILLION IN TOTAL POTENTIAL PAYMENTS

  • NURIX THERAPEUTICS - DEVELOPMENT COSTS SHARED 40% NURIX, 60% ROCHE; U.S. PROFITS AND LOSSES SPLIT EQUALLY

  • NURIX THERAPEUTICS - ROCHE TO CO-COMMERCIALIZE BEXOBRUTIDEG IN U.S.; ROCHE COMMERCIALIZES EX-U.S.; NURIX TO RECEIVE ROYALTIES

  • NURIX THERAPEUTICS - CO AND ROCHE TO JOINTLY ADVANCE BEXOBRUTIDEG IN CLL, B-CELL MALIGNANCIES, MS, AND CSU

Source text: ID:nGNXwTmbn

Further company coverage: NRIX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.